Metastasectomy, intralesional resection, or stabilization only in the treatment of bone metastases from renal cell carcinoma

J Surg Oncol. 2016 Aug;114(2):237-45. doi: 10.1002/jso.24284. Epub 2016 May 9.

Abstract

Background: The mainstay of treatment for bone metastases from renal cell carcinoma is surgery. We assessed if there was a difference in local recurrence, reoperation, and survival between patients who underwent metastasectomy, intralesional curettage, or stabilization only for renal cell carcinoma metastasis to the appendicular skeleton, and if there was a difference in these outcomes based on margin status.

Methods: This retrospective study included 183 patients; 48% underwent metastasectomy (n = 88, margins: 64 negative; 20 positive; 4 unclear), 30% intralesional curettage (n = 54), and 22% stabilization only (n = 41).

Results: The recurrence rate differed and was highest after stabilization only (39%), followed by intralesional curettage (22%), and metastasectomy (12%) (P = 0.003). However, we found no difference in reoperation rate (P = 0.847). Survival was better in patients who underwent metastasectomy (P = 0.020). The recurrence rate was lower in patients who had a negative margin (5%) as compared to those with a positive margin (26%) (P < 0.001). However, we found no difference in reoperation rate (P = 0.97). Negative margins showed better survival (P < 0.001).

Conclusions: Our findings emphasize the importance of obtaining negative margins in patients with a good life expectancy, as lower recurrence rate can be attained at a not significant additional risk for reoperation, with a potential impact on survival. J. Surg. Oncol. 2016;114:237-245. © 2016 Wiley Periodicals, Inc.

Keywords: bone metastasis; intralesional curettage; metastasectomy; renal cell carcinoma; resection.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Bone Neoplasms / mortality
  • Bone Neoplasms / secondary*
  • Bone Neoplasms / surgery
  • Carcinoma, Renal Cell / pathology*
  • Female
  • Follow-Up Studies
  • Humans
  • Kidney Neoplasms / pathology*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Reoperation
  • Retrospective Studies
  • Treatment Outcome